ATAI Life Sciences ( (ATAI) ) has issued an announcement.
atai Life Sciences, a biopharmaceutical company focused on mental health treatments, announced its third-quarter 2024 financial results and upcoming clinical trials. The company is set to begin Phase 2 trials for VLS-01 in treatment-resistant depression and EMP-01 for social anxiety disorder by the end of 2024. With FDA clearance for VLS-01 and a strategic acquisition of IntelGenx, atai is poised for significant advancements in psychedelic therapy. Despite a financial loss this quarter, atai remains funded through 2026, aiming to revolutionize mental health treatment.
See more insights into ATAI stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com